Classic Hodgkin lymphoma

This large phase 3 trial enrolled over 2900 children and teens with classical Hodgkin lymphoma. The goal was to see if doctors could reduce the use of radiation therapy without lowering cure rates. Some patients also received stronger chemotherapy to make up for less radiation. T…

This trial tests an experimental drug called FLX475, given alone or with the immunotherapy pembrolizumab, in people with advanced cancers that have not responded to standard treatments. The study aims to find the safest dose and to see whether the combination can shrink tumors. P…

This early-phase trial tests a new therapy for Hodgkin and non-Hodgkin lymphoma that has returned or not responded to standard treatment. Researchers take a patient's own immune cells, train them in the lab to recognize five cancer-specific proteins (tumor-associated antigens), a…

This phase 2 trial tests a new drug combination called MK-4280A (favezelimab plus pembrolizumab) against standard chemotherapy in people with classical Hodgkin lymphoma that has come back or stopped responding to treatment. About 200 participants will be randomly assigned to rece…

This trial tests whether combining two drugs, brentuximab vedotin (Adcetris) and bendamustine (Levact), can safely and effectively treat Hodgkin lymphoma in people aged 60 to 80 who have not had prior treatment. The standard therapy, ABVD, often causes lung damage in older adults…

This phase 2 trial tests a personalized approach for people with newly diagnosed, advanced classical Hodgkin lymphoma. After two cycles of standard chemotherapy, patients are grouped based on a PET scan. Those with a moderate response receive the immunotherapy drug sintilimab plu…

This Phase 3 trial tested a stem cell transplant using blood stem cells from a half-matched (haploidentical) donor in 21 people with various blood cancers. The goal was to see if this approach could help patients who don't have a fully matched donor. Participants received chemoth…

This study tested a new approach for people with both HIV and lymphoma. After high-dose chemotherapy and a stem cell transplant, participants received specially grown HIV-fighting immune cells (HST-NEETs). The goal was to see if giving these cells was feasible and if they could r…

This study tested a combination of brentuximab vedotin and AVD chemotherapy in 118 adults with newly diagnosed, early-stage Hodgkin lymphoma that is considered unfavorable. The goal was to see if this treatment could cure more patients while reducing long-term side effects, espec…

This study tested a new way to treat blood cancers like leukemia in 16 adults who did not have a standard bone marrow donor. Doctors used a single unit of cord blood that was grown in a lab to increase the number of stem cells before transplant. The goal was to see if this method…

This phase II trial tested a combination of the targeted drug brentuximab vedotin with standard chemotherapy (AVD) in 49 older adults with untreated Hodgkin lymphoma. The goal was to see how many patients achieved complete remission. The approach aims to improve outcomes by targe…

This study tested whether giving the immunotherapy drug pembrolizumab after a stem cell transplant could help keep lymphoma from coming back. It included 82 adults with relapsed or hard-to-treat Hodgkin lymphoma, diffuse large B-cell lymphoma, or T-cell lymphoma. The goal was to …

This phase 2 trial tested a drug called KL-A167 in 109 adults with classical Hodgkin lymphoma that had returned or not responded to prior treatments. Participants received the drug intravenously every two weeks. The main goal was to see how many patients' tumors shrank or disappe…

This early-phase trial tested the safety of combining two drugs—L-NMMA and pembrolizumab (Keytruda)—in 12 adults with various advanced cancers. Pembrolizumab helps the immune system recognize cancer cells, while L-NMMA may remove a chemical barrier that blocks immune attack. The …

This phase 2 trial tested a two-step stem cell transplant approach for 47 patients with high-risk blood cancers like leukemia and lymphoma. The method uses the drug cyclophosphamide to lower the chance of graft-versus-host disease (GVHD), a common complication. The goal was to se…

This study tested whether giving the drug brentuximab vedotin for up to a year after a stem cell transplant could help control Hodgkin lymphoma that had returned or not responded to treatment. 14 adults took part. The goal was to see if this approach could lower the chance of the…

This Phase 3 trial tested two chemotherapy combinations—BEGEV and GDP—in 88 adults with relapsed or refractory classical Hodgkin lymphoma. Patients received either regimen in 21-day cycles, and their response was checked with a PET scan after three cycles. Those who achieved at l…

This pilot study tested a combined bone marrow and kidney transplant from a partially matched family donor in 10 people with both a blood disorder and chronic kidney disease. The goal was to treat both conditions at once and possibly reduce the need for lifelong anti-rejection dr…

This large phase 3 trial tested a new drug combination (brentuximab vedotin plus AVD) against the standard ABVD regimen in 1,334 patients with advanced Hodgkin lymphoma. The goal was to see if the new combo could delay cancer progression better. Results showed improved progressio…

This study tested a new drug called MK-7684A, which combines two immune-boosting medicines (pembrolizumab and vibostolimab), in 192 people with blood cancers like lymphoma and multiple myeloma that had returned or stopped responding to prior treatments. The main goals were to see…

This completed Phase 3 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) works better than the targeted drug brentuximab vedotin (Adcetris) for people with classical Hodgkin lymphoma that has relapsed or not responded to prior therapy. 304 participants were ran…

This study tested whether using an early PET scan after two rounds of chemotherapy can help doctors choose the right treatment for people with advanced Hodgkin lymphoma. Patients whose scan showed a good response got a milder chemo, while those with less response continued strong…

This study tested the drug pembrolizumab (Keytruda) given every 6 weeks to 66 adults whose Hodgkin lymphoma or primary mediastinal large B-cell lymphoma had come back or not responded to prior treatment. The main goal was to see how many patients had their tumors shrink or disapp…

This study tested whether a targeted drug called brentuximab vedotin (SGN-35) could replace the standard ICE chemotherapy before a stem cell transplant in 66 people with relapsed or refractory Hodgkin lymphoma. The drug targets cancer cells and has fewer side effects than ICE. Pa…

This phase 1/2 trial tested a new treatment for people with CD30-positive Hodgkin or non-Hodgkin lymphomas that returned or didn't respond to prior therapy. The treatment combines AFM13, an antibody that targets cancer cells, with natural killer (NK) cells from donated umbilical …

This study tested a new drug called AZD7789 in 45 people with classical Hodgkin lymphoma that had returned or not responded to at least two prior treatments. The drug is a special antibody designed to help the immune system fight cancer cells. The main goals were to check safety …

This Phase 2 trial tested the drug tislelizumab in 46 people with classical Hodgkin lymphoma that had come back or was not responding to treatment. The main goal was to see how many participants had their tumors shrink or disappear. Participants received the drug every 3 weeks un…

This study compared two chemotherapy regimens for people with advanced classical Hodgkin lymphoma. One group received the standard ABVD regimen, while the other received a newer combination called BV+AVD, which includes the targeted drug brentuximab vedotin. The trial enrolled 60…

This study tested a tool built into electronic health records that prompts doctors to discuss heart health with cancer survivors during routine visits. Researchers enrolled 645 survivors of breast, prostate, colorectal, endometrial, and lymphoma cancers across 12 clinics. The goa…

This study looked at 137 adults with newly diagnosed classical Hodgkin lymphoma to see if a specific genetic change (XPO1 E571K) found in their blood could signal whether cancer remains after chemotherapy. Researchers compared the blood test results with standard PET scans to mea…

This pilot study tested whether a WHOOP wrist monitor can reliably measure resting heart rate and heart rate variability in 34 adult survivors of Hodgkin lymphoma who had chest radiation. Participants wore the monitor at home and also had in-office measurements. The goal was to s…